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This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based 
research. The summary is not intended to be a comprehensive summary of available evidence on 
COVID-19 but aims to make original documents easily accessible to decision makers which, if 
relevant to them, they should go to before making decisions. 

















• Survey of 3,904 
COVID-19 survivors 
between May 2020 
and January 2021 in 
the US found that 
52.4% met the criteria 
for moderate or 
greater symptoms of 
major depression  
• These symptoms were 




men compared with 
women and among 
those with more 
severe COVID-19 
illness compared with 
lower severity 
• Authors highlight the 
importance of 
considering strategies 
that might mitigate the 

















• People who have 
diabetes, high blood 
pressure or pre-
existing heart 
problems are at 
greater risk of 
developing 
complications if they 
get COVID-19 
• This systematic review 
wanted to find out, in 
cases of confirmed or 
suspected COVID-19, 
what are the most 
common pre-existing 
heart and blood vessel 
problems and what 
are the most common 
complications affected 
the heart and blood 




common in people 
who are hospitalised 





• The studies were very 
different from each 
other, did not always 
reports results in the 
same way or use the 
most reliable methods 
• This review will be 
updated with a formal 
meta-analysis of 
outcomes based on a 
more homogeneous 




10.03.2021 What is the 
recovery rate 







BMJ Open | 
Protocol 
• The assessment of 
risk factors for longer 
term consequences of 
COVID-19 requires a 
longitudinal study 
linked to data on pre-
existing conditions 
and care received 
during the acute 














sequelae in patients 
post-COVID-19 
hospital discharge 
• The open access 
follow-up survey can 
be used by other 
follow-up studies to 
facilitate standardised, 
multisite data 
collection to forward 
knowledge into long-
term consequences of 
COVID-19 





















• The SARS-CoV-2 VOC-
202012/1, first detected in 
SE England in autumn 2020 
and now spread to 100+ 
countries, is more 
transmissible than 
previously circulating 
variants and is known to 
increase mortality but before 
this study, unbiased 
estimates of the mortality 
were not available 
• Cohort study of 54,906 
matched pairs of participants 
who tested positive for 
SARS-CoV-2 in community 
testing centres in UK 
between 1 October 2020 
and 29 January 2021, 
followed-up until 12 
February 2021 
• Individuals infected with 
SARS-CoV-2 VOC-
202012/1, were between 
32% to 104% (central 
estimate 64%) more likely to 
die than matched individuals 
UK variant, 
mortality 
with previously circulating 
SARS-CoV-2 variants 
• Absolute risk of death in this 
largely unvaccinated 
population remains low, but 
clinicians and public health 
officials should be aware 
that a higher mortality rate is 

















• Number of SARS-CoV-2 
infections in Zambia are 
likely to be higher than 
confirmed cases counts 
(20,000 laboratory-
confirmed cases between 
March and December 2020) 
because many infected have 
mild or no symptoms and 
due to limited testing 
capacity and surveillance 
systems 
• Here, a population-based 
household survey was used 
to estimate SARS-CoV-2 
prevalence in six districts of 
Zambia in July 2020 
• 4258 people from 1866 
households participated 
• An estimated 454,708 
SARS-CoV-2 infections 
(95% CI 312,705 to 
596,713) occurred in the six 
districts between March and 
July 2020, much higher 
when compared with 4917 
laboratory-confirmed cases 
reported in official statistics 
from the Zambia National 























• Meta-analysis of 404 
published and preprint 
serological studies from 
across the globe 
• A higher prevalence of 
SARS-CoV-2-specific 
antibodies was observed in 
close contacts (18.0%) and 
high-risk health care workers 
(17.1%) than in low-risk 
health care workers (4.3%) 
and the general population 
(8.0%) – far from herd 
immunity 
serology 
• Seroprevalence of general 
populations varied across 
WHO regions – highest in 
the South-West Asia region 
(19.6%) and the lowest in 
Western Pacifica region 
(1.7%) 
• Young (<20 years) and older 
(>=65y) were less likely to 
be seropositive than those 
aged 20-64y 
• No significant difference 
between men and women 
• Authors call for international 
collaborations to standardise 
serological survey and 
laboratory methods given 
the general low quality of 
studies 
• Accompanying commentary 
(see below) notes that 
waning of antibodies 
suggest seroprevalence 
data may underestimate true 
number of infections and 
antibody tests don’t measure 






















• Convalescent plasma 
has been widely used 






platform trial to 
evaluate the safety 
and efficacy of 
convalescent plasma 
in patients admitted to 
hospital with COVID-
19 




did not improve 
Convalescent 
plasma 

























B.1.1.7 and B.1.351 






with a single dose of 
ChAdOx1 nCoV-19 
has been shown 
• Lack of disease in 
hamsters vaccinated 
with ChAdOx1 nCoV-
19 when infected with 
B1.1.7 or B.1.351 
demonstrate the 

























• Various vaccine 
deployment strategies 
are being proposed 
due to vaccine dose 
shortages and 
logistical challenges 
• Two critical issues: 
how will timing of 
delivery of the second 
does affect immunity 
and evolution of viral 
immune escape from 
a build-up of partially 
immune individuals 











outcomes depend on 
relative immune 
robustness 
• Exploring three 
scenarios, a one-dose 
policy may increase 
the potential for 
antigenic evolution 
under certain 
conditions of partial 
population immunity 












phase 2 trial, 
and 3-month 
follow-up of a 
double-blind, 
randomised 





• Report on interim 
findings of the phase 
2 trial on the 
immunogenicity and 
safety of BBV152, a 
whole-virion 
inactivated SARS-
CoV-2 vaccine, with 
first dose 
administered on day 0 
and the second dose 
on day 28 
• In the phase 1 trial, 
BBV152 induced high 
neutralising antibody 
responses which 
remained elevated in 
all participants 3 
months after the 
second dose 
• In the phase 2 trial, 
BB152 showed better 
reactogenicity and 
safety outcomes and 
enhanced immunity 
compared with the 
phase 1 trial 
• This vaccine 
candidate (6ug with 
Algel-IMDG 
formulation) is now in 




























• Disruptions to maternity 
care caused by the 
COVID-19 pandemic have 
been surveyed but not 
those related to vulnerable 
small newborns 
• Using a widely 
disseminated online survey 
in three languages, this 




analysis of healthcare 
providers’ experiences and 
proposed mitigation 
strategies 
• Analysis of 1120 
responses from 62 
countries, mainly LMICs 
• Newborn care providers 
are stressed and 
compromised and there is 
a lack of clarity and 
guidelines regarding care 
of small newborns during 
the pandemic 
• Life-saving interventions, 











WHO | Report 
• Data from the largest study 
to-date, conducted by 
WHO on behalf of a 
special working group of 
the UN, of the prevalence 
of violence against women 
• Based on data from 2000 
to 2018 – a update on 
previous estimates 
released in 2013 
• Numbers though do not 
reflect ongoing impact of 
the COVID-19 pandemic 
which has further 
increased women’s 
exposure to violence due 
to non-pharmaceutical 




lockdowns and disruptions 























• Analysis of the role and 
weaknesses of primary 
and community 
healthcare worldwide 
• This paper proposes that 
primary and community 
healthcare should (i) 
support local problem-
solving efforts and serve 




and (ii) understand the 
local environment and 
health risks in the 






Comments, Editorials, Opinions, Blogs, News 
Publication 
date 
Title/URL Journal | Article type 
15.03.2021 German, France and Italy suspend Oxford Covid 
vaccine 
The Guardian | News 
March 2021 Measles: the long walk to elimination drawn out by 
COVID-19 
The Lancet Global Health 
| Comment 
15.03.2021 Regular booster vaccines are the future in battle with 
COVID-19 virus, expert says 
Reuters | News 
12.03.2021 Ghana’s COVID-19 response: the Black Star can do 
even better 
BMJ Global Health | 
Commentary 
12.03.2021 COVID antibody treatments show promise for 
preventing severe disease 
Nature | News 
12.03.2021 Long Covid more likely in working-age women than 
in men – study 
The Guardian | News 
11.03.2021 Is Covid-19 reshaping our approach to development 
research? 
IDS | Opinion (Peter 
Taylor) 
11.03.2021 COVID-19 cases in Africa to top 4 million, vaccine 
rollout underway 
WHO Africa | News 
11.03.2021 Redressing the impact of COVID-19 on medical 
education in Africa: the need for collective action 
BMJ Global Health | 
Commentary 
10.03.2021 Deadly pig disease could have led to Covid spillover 
to humans, analysis suggests 
The Guardian | News 
09.03.2021 Mitigating gender-based violence risk in the context 
of COVID-19: lessons from humanitarian crises 
BMJ Global Health | 
Commentary 
09.03.2021 3 medical innovations fueled by COVID-19 that will 
outlast the pandemic 
The Conversation 
09.03.2021 Understanding the impact of COVID-19 on the 
private health sector in Africa 
BMJ Global Health | Blog 
08.03.2021 COVID-19 serosurveys for public health decision 
making 
The Lancet Global Health 
| Commentary 
08.03.2021 A moral failure in pandemic response CGD | Blog 
08.03.2021 Financing for Global Health Security and pandemic 
preparedness: taking stock and what’s next 
CGD | Blog 
05.03.2021 Overcoming the gender gap in Covid experience IDS | News 
04.03.2021 Covid-19: A stress test for trust?  IDS | Briefing 
   
 
Dashboards & Trackers   












  Diagnostics   Treatments   Vaccines 
WHO sitreps  WHO Africa  Ghana  COVID-NMA  WHO    FIND SARS-
CoV-2 Test 
Tracker 
  Global COVID-
19 Clinical Trial 
Tracker 
  CEPI 
WHO dashboard  African 
Arguments  


















Nigeria CDC  Norwegian 
Institute of Public 
Health  
Cytel   Serology-based 
tests for COVID-
19 
  Solidarity trial  COVID-19 
Oxford Vaccine 
Trial 





US NIH   Our World in 
Data: C19 
Testing 





Our World in 
Data  
  Singapore   Our World in 
Data: C19 Policy 
responses 
COVID-evidence      Our World in 
Data: COVID-
19 vaccinations  
Global 5050    UK   IFPRI COVID-19 
Policy Response 
Portal 




  US   COVID-19 
Primer 
Clinicaltrials.gov        
Humanitarian 
Data Exchange  
     NIH LitCovid  UKCDR       
Information is 
Beautiful  
     WHO COVID-19 
Database 
        
LSHTM                
HealthMap 
(cases) 
              
The Commons 
Project 
              
SeroTracker                
   
 
C19 Resource Hubs 

















LSTM Stop TB 
Partnership 








  IDA 
WHO Q&A Nigeria 
CDC 
Bulletin of the 
WHO 












































































and Planning  
Norwegian 
Institute of Public 
Health 
    




JAMA Network Oxford Centre for 
Evidence-based 
Medicine 
    
UNICEF   The Lancet  HEART     
UNESCO   medRxiv and 
bioRxiv 
(Preprints) 
 UKRI     
UN WFP   NEJM  Evidence Aid     
GOARN   Oxford 
University 
Press 
 NIH     
EPI-WIN   PLoS IFPRI Resources 
and Analyses of 
C19 Impact 
    
World Bank   SAGE journals  Prevent 
Epidemics  
    
Our World in 
Data 





  Springer Nature       
Reliefweb   SSRN 
(Preprints)  













      
WorldPop           
Flowminder           





    
  
GISAID           
  
Online learning & events 





Africa taking charge of 
its future: prioritizing 
gender equality in the 
path to recovery 
Webinar 1h 30 CGD 
10 March 
2021 
Equity and scale in 
global immunization: 
new evidence from 
Nigeria on cash 
transfers for vaccination 
Webinar 1h 15 CGD 
9 March 
2021 
COVID-19 vaccines and 
Africa: where do we 









Diseases in the COVID 
era 




training for health 
workers 
Online training 3h  WHO 
14.01.2021 Evidence to impact in 
crisis: how have we 
measured up during the 
COVID-19 pandemic? 
Webinar 1h 30 CGD 
04.12.2020 COVID-19, supply chain 
resilience and global 
trade 
Webinar 1h CGD 
03.12.2020 More money for health 
services: What is the 
tole of PFM in the “new 
normal”? 




1h 30 Joe Kutzin 
01.12.2020 Solutions and support 
for the mental wellbeing 
of community health 
workers on the COVID-
19 frontline 
Webinar   HSG TWG on CHWs 
with The George 
Institute for Global 
Health 
19.11.2020 Looking at the pandemic 
with a gender lens 
Live Twitter 
conversation 
  SSHAP 
16.11.2020 HIFA and WHO 
collaborate to promote 
sharing of experience 
and expertise around 
the maintenance of 
essential health services 




starting 16 Nov 
  HIFA 
10.11.2020 COVID-19 vaccine 
predictions part 2: 
estimating the time 
before we approve 
efficacious COVID-19 
vaccines 
Online event 1h30 CGD 
16.10.2020 Financing a Global 
Public Health Response 
Online event 1h30 CGD 
02.10.2020 Understanding and 
Improving COVID-19 
Vaccine Portfolio 
Online event 1h30 CGD 
21.09.2020 Mitigating the Economic 
and Health Impact of 
COVID-19 across Africa 
Online event 1h30 CGD, GF, AU 
June 2020 OpenWHO, the free, 
open-access learning 
platform for health 
emergencies, now offers 
10 online courses 
related to COVID19. 










Nursing in Times of 
Crisis 






School of Nursing 
Available 
now 
WHO Academy and 
WHO Info mobile 
applications 




Modelling and Policy 
Online learning 2 weeks 








11.5.2020 COVID-19 Contact 
Tracing course 
Online learning 5 hours Johns Hopkins 




Virtual Evidence Weeks 5 sessions 1h 30 International Initiative 











COVID-19 Open online 
brief with Dr David 
Nabarro 





COVID-19: methods for 
detection, prevention, 
response and control 




19: Real-time training 
for the coronavirus 
disease outbreak 







COVID-19: Tackling the 
Novel Coronavirus 
Online learning 3 weeks 
















Online learning 3 weeks 







COVID-19 Critical Care: 
Understanding and 
Application 
Online learning 5 weeks 





Edinburgh & Royal 
College of Physicians 
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Rapid review methodology 
The rapid weekly search for peer-reviewed literature is carried out through a PubMed search with the following 
keywords (“COVID-19” OR “severe acute respiratory syndrome coronavirus 2” OR “2019-nCoV” OR “SARS-CoV-
2” OR “2019nCoV” OR “coronavirus” ) AND (“Africa” OR “South Asia” OR “Developing” OR “low-income” OR “low 
income” OR “lower-middle income” OR “low and middle income” OR “LMIC” OR “LIC” OR “global south”) OR 
(“poverty”) OR (“equity” OR “equities”), restricted to articles published in the previous 2 to 3 days, in English. This 
is complemented by a search of the homepage of the following high-impact global health journals: The Lancet 
journals, New England Journal of Medicine, Nature, JAMA, Annals of Internal Medicine, Cochrane Reviews, BMJ 
Global Health, the PLoS journals and a Twitter search of their Twitter pages. A search also of preprints from bioRxiv 
and medRxiv. Please note that papers that have not been peer-reviewed are highlighted in red. All primary 
research papers that relate to the primary and secondary impacts of the COVID-19 response in LMICs, and disease 
control and health system responses are included. Articles related to tackling the secondary impacts on other 
sectors are not included. Additional commentaries, opinions, and commissioned pieces are selected based on 
relevance. 
  
The search for dashboards, guidelines, tools, editorials, comments, blogs, opinions and news is through the 
academic journals listed above, C19 resource hubs and following lead academics and professionals on Twitter. 
 
About this report  
This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based research. The 
summary is not intended to be a comprehensive summary of available evidence on COVID-19 but aims to make 
original documents easily accessible to decision makers which, if relevant to them, they should go to before 
making decisions. The HES are not intended to replace medical or professional advice and the researcher or the 
K4D consortium cannot be held responsible for any decisions made about COVID-19 on the basis of the HES 
alone. K4D services are provided by a consortium of leading organisations working in international development, 
led by the Institute of Development Studies (IDS), with Education Development Trust, Itad, University of Leeds 
Nuffield Centre for International Health and Development, Liverpool School of Tropical Medicine (LSTM), 
University of Birmingham International Development Department (IDD) and the University of Manchester 
Humanitarian and Conflict Response Institute (HCRI). 
This evidence summary was prepared for the UK Government’s Foreign, Commonwealth 
and Development Office (FCDO) and its partners in support of pro-poor programmes. Except 
where otherwise stated, it is licensed for non-commercial purposes under the terms of the 
Open Government Licence v3.0. K4D cannot be held responsible for errors, omissions or 
any consequences arising from the use of information contained in this health evidence 
summary. Any views and opinions expressed do not necessarily reflect those of FCDO, K4D 
or any other contributing organisation.  
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